반응 #816383
ord-105bc92990b24b3d9a6b481443a8c1a0
반응 조건
후처리
- 1기타fitted with a USP induction port (<USP 601> Pharmacopeial Previews 22, 3065 (1995))
- 2여과filter
- 3기타were actuated per test, with an interval of at least 30 seconds between shots
- 4온도to prevent cooling of the can
- 5기타resultant moisture condensation
- 6여과filter (corresponding to particles of MMAD less than 3.3 μm)
실험 절차
The formulations were tested on an Andersen™ cascade impactor to determine their aerodynamic particle properties. The cascade impactor was operated at 28.3 I/min and fitted with a USP induction port (<USP 601> Pharmacopeial Previews 22, 3065 (1995)). The particle size distributions were fractionated into mass of drug deposited on the pMDI actuator, USP induction port, eight stages and terminal filter. Five shots were actuated per test, with an interval of at least 30 seconds between shots to prevent cooling of the can and resultant moisture condensation. The bromocriptine content in each sample was determined by HPLC. The percentage of the total dose deposited from stage 4 to the terminal filter (corresponding to particles of MMAD less than 3.3 μm) was considered to be the fine particle fraction.